JP2014503480A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014503480A5 JP2014503480A5 JP2013536727A JP2013536727A JP2014503480A5 JP 2014503480 A5 JP2014503480 A5 JP 2014503480A5 JP 2013536727 A JP2013536727 A JP 2013536727A JP 2013536727 A JP2013536727 A JP 2013536727A JP 2014503480 A5 JP2014503480 A5 JP 2014503480A5
- Authority
- JP
- Japan
- Prior art keywords
- deuterium
- rich
- pharmaceutical composition
- compound
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- PIXDGZHWRVYNAU-UHFFFAOYSA-N C=NC(C#C)(C#C)N=O Chemical compound C=NC(C#C)(C#C)N=O PIXDGZHWRVYNAU-UHFFFAOYSA-N 0.000 description 1
- QUUSLJRWTDZCBF-UHFFFAOYSA-N OC1(c2ccccc2CC1)O Chemical compound OC1(c2ccccc2CC1)O QUUSLJRWTDZCBF-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40674010P | 2010-10-26 | 2010-10-26 | |
| US61/406,740 | 2010-10-26 | ||
| PCT/US2011/057698 WO2012058219A2 (en) | 2010-10-26 | 2011-10-25 | Deuterium enriched rasagiline |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014503480A JP2014503480A (ja) | 2014-02-13 |
| JP2014503480A5 true JP2014503480A5 (enExample) | 2014-12-11 |
Family
ID=45973513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013536727A Pending JP2014503480A (ja) | 2010-10-26 | 2011-10-25 | ジュウテリウムリッチなラサギリン |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20120101168A1 (enExample) |
| EP (1) | EP2632254A4 (enExample) |
| JP (1) | JP2014503480A (enExample) |
| KR (1) | KR20140023872A (enExample) |
| CN (1) | CN103188933A (enExample) |
| AU (1) | AU2011320611A1 (enExample) |
| BR (1) | BR112013010308A2 (enExample) |
| CA (1) | CA2816104A1 (enExample) |
| CL (1) | CL2013001101A1 (enExample) |
| EA (1) | EA201390613A1 (enExample) |
| IL (1) | IL225852A0 (enExample) |
| MX (1) | MX2013004598A (enExample) |
| NZ (1) | NZ610526A (enExample) |
| PH (1) | PH12013500821A1 (enExample) |
| SG (2) | SG189454A1 (enExample) |
| WO (1) | WO2012058219A2 (enExample) |
| ZA (1) | ZA201303505B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1991214B1 (en) * | 2006-02-21 | 2015-08-05 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
| EP2007369A4 (en) * | 2006-04-03 | 2009-07-01 | Teva Pharma | USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST |
| RS52183B (sr) * | 2006-12-14 | 2012-10-31 | Teva Pharmaceutical Industries, Ltd. | Kristalna čvrsta baza razagilina |
| EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
| WO2009089049A1 (en) * | 2008-01-11 | 2009-07-16 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations, their preparation and use |
| US20100008983A1 (en) * | 2008-06-10 | 2010-01-14 | Muhammad Safadi | Rasagiline soft gelatin capsules |
| DK2451771T3 (da) | 2009-07-09 | 2014-09-08 | Ratiopharm Gmbh | Salte af rasagilin og farmaceutiske fremstillingsmåder heraf |
| AU2010304755A1 (en) * | 2009-10-09 | 2012-05-24 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of Progressive Supranuclear Palsy |
| EP2515891A4 (en) * | 2009-12-22 | 2013-06-05 | Teva Pharma | 3-keto-N-propargyl-1-aminoindan |
| RU2587330C2 (ru) | 2010-07-27 | 2016-06-20 | Тева Фармасьютикал Индастриз Лтд. | Применение разагилина для лечения обонятельной дисфункции |
| WO2012015946A1 (en) | 2010-07-27 | 2012-02-02 | Teva Pharmaceutical Industries Ltd. | Dispersion of rasagiline citrate |
| HK1200314A1 (en) | 2011-10-10 | 2015-08-07 | Teva Pharmaceuticals Usa, Inc. | R(+)-n-methyl-propargyl-aminoindan |
| HK1200315A1 (en) | 2011-10-10 | 2015-08-07 | Teva Pharmaceutical Industries Ltd. | R(+)-n-formyl-propargyl-aminoindan |
| US9308182B2 (en) | 2012-08-17 | 2016-04-12 | Teva Pharmaceutical Industries, Ltd. | Parenteral formulations of rasagiline |
| BR112021010923A2 (pt) * | 2018-12-06 | 2021-08-24 | Intrabio Ltd | Análogos deuterados de acetileucina |
| CN111323524B (zh) * | 2020-04-08 | 2022-04-15 | 重庆华森制药股份有限公司 | 一种炔丙胺及其杂质的检测方法 |
| CN115947675B (zh) * | 2022-12-21 | 2024-05-31 | 博济医药科技股份有限公司 | 一种雷沙吉兰中间体及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL92952A (en) | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
| US5744500A (en) | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| EP1778196A4 (en) * | 2004-07-26 | 2008-12-17 | Teva Pharma | PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE |
| US20090111892A1 (en) * | 2004-11-24 | 2009-04-30 | Shulamit Patashnik | Rasagiline Orally Disintegrating Compositions |
| CA2600008A1 (en) * | 2005-02-22 | 2006-11-16 | Teva Pharmaceutical Industries Ltd. | Improved process for the synthesis of enantiomeric indanylamine derivatives |
| JP2009514946A (ja) * | 2005-11-06 | 2009-04-09 | ブレイン ウォッチ エルティディ | 磁気共鳴画像／分光手段およびその方法 |
| NZ589470A (en) * | 2008-06-02 | 2012-08-31 | Generics Uk Ltd | A process for the preparation of rasagiline and its analogues |
| BRPI0909894A2 (pt) * | 2008-06-13 | 2015-07-28 | Teva Pharma | "método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica. |
| US20100172916A1 (en) * | 2008-11-10 | 2010-07-08 | Auspex Pharmaceuticals, Inc. | Substituted hydroxyphenylamine compounds |
| US20100189791A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline malate formulation |
| US20100286124A1 (en) * | 2009-04-10 | 2010-11-11 | Auspex Pharmaceuticals, Inc. | Prop-2-yn-1-amine inhibitors of monoamine oxidase type b |
| EP2473199A1 (en) * | 2009-08-31 | 2012-07-11 | Brain Watch Ltd. | Isotopically labeled neurochemical agents and uses thereof for diagnosing conditions and disorders |
-
2011
- 2011-10-25 MX MX2013004598A patent/MX2013004598A/es not_active Application Discontinuation
- 2011-10-25 BR BR112013010308A patent/BR112013010308A2/pt not_active IP Right Cessation
- 2011-10-25 CA CA2816104A patent/CA2816104A1/en not_active Abandoned
- 2011-10-25 SG SG2013029293A patent/SG189454A1/en unknown
- 2011-10-25 KR KR1020137013167A patent/KR20140023872A/ko not_active Withdrawn
- 2011-10-25 AU AU2011320611A patent/AU2011320611A1/en not_active Abandoned
- 2011-10-25 EA EA201390613A patent/EA201390613A1/ru unknown
- 2011-10-25 EP EP11836950.3A patent/EP2632254A4/en not_active Withdrawn
- 2011-10-25 CN CN2011800519198A patent/CN103188933A/zh active Pending
- 2011-10-25 WO PCT/US2011/057698 patent/WO2012058219A2/en not_active Ceased
- 2011-10-25 NZ NZ610526A patent/NZ610526A/en not_active IP Right Cessation
- 2011-10-25 PH PH1/2013/500821A patent/PH12013500821A1/en unknown
- 2011-10-25 US US13/281,054 patent/US20120101168A1/en not_active Abandoned
- 2011-10-25 SG SG10201508771TA patent/SG10201508771TA/en unknown
- 2011-10-25 JP JP2013536727A patent/JP2014503480A/ja active Pending
-
2013
- 2013-04-21 IL IL225852A patent/IL225852A0/en unknown
- 2013-04-22 CL CL2013001101A patent/CL2013001101A1/es unknown
- 2013-05-14 ZA ZA2013/03505A patent/ZA201303505B/en unknown
-
2014
- 2014-06-20 US US14/310,321 patent/US20140364506A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5373405B2 (ja) | 選択的アンドロゲン受容体モジュレーター | |
| EP2912047B1 (en) | Antiviral phosphonate analogues and process for preparation thereof | |
| IL255433B2 (en) | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine | |
| JP5468608B2 (ja) | ４−オキソ−オクタヒドロ−インドール−１−カルボサイリックアシッドメチルエステルとその誘導体の調製方法 | |
| JP2020520946A5 (enExample) | ||
| EP4293009A2 (en) | Fenfluramine compositions and methods of preparing the same | |
| WO2019177975A1 (en) | Antibiotics effective for gram-negative pathogens | |
| JP2009542613A5 (enExample) | ||
| CN103188933A (zh) | 富集氘的雷沙吉兰 | |
| JP2014510746A5 (enExample) | ||
| TW201420586A (zh) | 抗病毒化合物之固體形式 | |
| JP2007522162A5 (enExample) | ||
| JP5955364B2 (ja) | 中間体として有用な新規化合物 | |
| JP2018510189A5 (enExample) | ||
| KR20170002433A (ko) | 의약으로 사용하기 위한 펄린돌 광학이성질체의 약학적으로 허용가능한 염 | |
| JP6522094B2 (ja) | ４−［２−ジメチルアミノ−１−（１−ヒドロキシシクロヘキシル）エチル］フェニル４−メチルベンゾエートヒドロクロリドの多形体、それらを作製する方法及びそれらの使用 | |
| CN108210933B (zh) | 一种地佐辛与聚乙二醇的结合物 | |
| CN103764608B (zh) | 用于治疗炎性肠病的茚衍生物 | |
| JPS60116678A (ja) | ｎ‐プロパノールアミン誘導体エーテル | |
| CN111909174A (zh) | 吡啶酮衍生物的晶型及制备方法和应用 | |
| JP5863846B2 (ja) | イリノテカンの製造方法 | |
| TW202608850A (zh) | 降冰片烷衍生物及其藥物用途 | |
| TW202345839A (zh) | 用於製造３，６－二取代－咪唑并［１，２－ｂ］嗒𠯤化合物之方法 | |
| CN102633852A (zh) | 亚胺类豆甾醇衍生物及其在抗癌药物中的应用 | |
| CN114286811A (zh) | 富马酸单甲酯的前药 |